MOTS-C

MOTS-C Peptide: Mechanism, Benefits & UK Research Status

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the MT-RNR1 gene of the 12S rRNA region. It acts on the folate–purine cycle to activate AMP-activated protein kinase (AMPK) and shift cellular metabolism toward glucose utilisation and fatty-acid oxidation [6]. In rodents, intraperitoneal MOTS-c at 5 mg/kg daily improved insulin sensitivity and exercise capacity in high-fat-diet mice (Lee et al., 2015) [1]. As of early 2026, no completed peer-reviewed interventional trials in humans exist [4][5]. In the UK, MOTS-c holds no MHRA marketing authorisation and is available only as a research peptide. WADA classifies it as prohibited at all times under Section 4.4.1, AMPK activators, within the metabolic modulators category [5].

Key Takeaways

• MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK through the folate–purine pathway.
• All efficacy data come from rodent studies or cultured cells; no human interventional trials have been completed as of early 2026.
• Endogenous MOTS-c declines with age and correlates with insulin resistance in observational human cohorts, but exogenous dosing has never been tested in humans.
• MOTS-c is prohibited in sport under WADA Section 4.4.1 and has no MHRA marketing authorisation in the UK.
• Theoretical risks include hypoglycaemia (from AMPK activation) and injection-site reactions, but human safety data do not exist.
• JCSG.org stocks Body Pharm MOTS-c — order direct for UK delivery.

What Is MOTS-c? A Plain-English Definition

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) with the sequence MRWQEMGYIFYPRKLR, encoded by the MT-RNR1 gene within the 12S rRNA region of the mitochondrial genome rather than the nuclear genome [5][6]. Lee and colleagues first characterised it in Cell Metabolism in 2015, which remains the foundational reference for its discovery and metabolic role [6].

That mitochondrial origin matters mechanistically. Unlike nuclear-encoded peptides translated in the cytosol from messenger RNA, MOTS-c belongs to a small family of MDPs (alongside Humanin and the SHLP series) whose open reading frames sit inside mitochondrial ribosomal RNA genes. This arrangement allows the organelle itself to issue retrograde signals to the rest of the cell [6][7]. The peptide then traffics out of the mitochondrion to act on cytosolic and nuclear targets in the folate–purine–AMPK axis.

For readers building a broader picture, browse our full peptides research library on JCSG.org and order whichever compounds suit your research programme.

Where MOTS-c Comes From: The MT-RNR1 Gene

MOTS-c is encoded by a small open reading frame (sORF) inside the MT-RNR1 gene, which itself codes for the 12S mitochondrial ribosomal RNA. This makes MOTS-c one of very few known bioactive peptides whose blueprint sits within an rRNA gene rather than a conventional protein-coding locus [6][1]. When Lee and colleagues reported this in Cell Metabolism in 2015, the finding forced a partial rethink of how compactly the 16,569-base-pair mitochondrial genome stores functional information [6].

The human mitochondrial genome is circular, double-stranded, and carries only 37 genes: 13 protein-coding sequences for oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs (12S and 16S). Embedding a peptide-coding sORF inside the 12S rRNA gene means the same stretch of DNA serves two functions — structural rRNA on one hand, MOTS-c template on the other. This dual-use economy is one reason the discovery attracted attention as a meaningful exception to the classical "one gene, one product" framing [1][6].

Maternal inheritance and inter-individual variation

Because mitochondrial DNA is inherited almost exclusively from the mother, MT-RNR1 sequence variants — and therefore potential differences in MOTS-c expression or stability — track maternal lineages rather than Mendelian patterns. The 2023 Frontiers in Endocrinology review notes that endogenous circulating MOTS-c declines with age and correlates with insulin resistance, but inter-individual baselines vary widely. This variation is consistent with both mtDNA haplogroup background and tissue-specific transcription [1].

Contrast with nuclear-encoded peptides

Nuclear-encoded peptides are transcribed in the nucleus, spliced, exported, and translated on cytosolic ribosomes. MOTS-c, by contrast, is transcribed and translated inside the mitochondrion before trafficking outward to engage the folate–purine–AMPK axis covered later.

How MOTS-c Works: The AMPK–Folate–Purine Pathway

MOTS-c activates AMP-activated protein kinase (AMPK) indirectly by disrupting the folate cycle, depleting purine biosynthesis intermediates, and triggering accumulation of AICAR — an endogenous AMPK agonist [1][4]. This four-step chain, rather than direct receptor binding, distinguishes MOTS-c from most signalling peptides characterised before 2015.

Under resting conditions, MOTS-c is translated inside the mitochondrion and exported to the cytosol at low basal levels. Under metabolic stress — glucose restriction, exercise, or oxidative challenge in the Lee et al. 2015 mouse and myocyte experiments — a fraction of cytosolic MOTS-c translocates into the nucleus. There it engages stress-responsive transcription factors and modulates expression of nuclear genes governing metabolic adaptation [1][4]. That nuclear translocation step was the landmark finding. Prior mitochondrial-derived peptides such as Humanin act extracellularly or at organelle membranes, whereas MOTS-c crosses into the nucleus to influence transcription directly [1].

From folate cycle disruption to AICAR accumulation

The cytosolic pool of MOTS-c interferes with one-carbon (folate) metabolism, specifically the methionine and purine biosynthesis branches. Reduced flux through de novo purine synthesis causes 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to build up [1][4]. AICAR is a well-characterised AMP mimetic. It allosterically activates AMPK in the same manner as the research tool compound of the same name used in metabolic pharmacology since the 1990s.

Why AMPK activation matters metabolically

AMPK is the cell's master energy sensor. Once activated, it promotes GLUT4 translocation and glucose uptake in skeletal muscle, increases fatty acid oxidation via ACC inhibition, suppresses gluconeogenic gene expression in liver, and improves insulin sensitivity at the receptor and post-receptor level [1][4]. In Lee et al.'s 2015 mouse work, 5 mg/kg intraperitoneal MOTS-c reversed high-fat-diet-induced insulin resistance and improved exercise capacity, with AMPK phosphorylation as the proximal readout [1][4]. The downstream profile overlaps substantially with metformin's mechanism, which is why MOTS-c is frequently described as an endogenous metformin-like signal.

Mechanistic confidence: what is rodent, what is human

The AMPK–folate–purine chain is established in mouse models and cultured human cell lines, not in living humans. As of early 2026 there are no interventional human studies confirming that exogenous MOTS-c activates AMPK in human tissue with the same kinetics or magnitude [1][4].

MOTS-c Benefits: What the Evidence Actually Shows

No MOTS-c benefit has been confirmed in a human randomised controlled trial as of early 2026. The reported effects below are drawn almost entirely from rodent models, cultured human cells, and observational human cohorts measuring endogenous peptide levels. Each claim is graded by study type and year so the strength of inference is explicit.

Evidence quality at a glance

Insulin sensitivity and metabolic regulation

The foundational finding is rodent. Lee et al. administered MOTS-c at 5 mg/kg intraperitoneally to high-fat-diet mice and reversed diet-induced insulin resistance, with AMPK phosphorylation as the proximal readout [1][3]. Parallel human muscle cell work showed increased glucose uptake [3]. No interventional human trial has reproduced this in vivo [1][4].

Exercise performance and physical endurance

Reynolds et al., published in Nature in 2021, reported that MOTS-c injection improved running capacity in young, middle-aged, and aged mice, with the largest relative gains in older animals [1][4]. The exact mg/kg dose in Reynolds et al. is not clearly stated in publicly available summaries and should be treated as unverified pending the primary text. Human endurance data do not exist.

Metabolic flexibility and fat oxidation

The 2023 Frontiers in Endocrinology review by Zheng and colleagues synthesises rodent evidence that MOTS-c shifts substrate use toward fatty acid oxidation, reduces hepatic lipid accumulation, and improves lipid profiles in obese mice [3]. Mechanistically this is consistent with the AMPK → ACC inhibition chain covered earlier. The review explicitly notes clinical translation remains absent [3].

Ageing and longevity signals

The Alzheimer's Drug Discovery Foundation's 2023 Cognitive Vitality profile concludes that MOTS-c "therapeutic safety has not been established" in humans and that longevity claims rest on rodent lifespan and healthspan data plus observational cohorts where endogenous MOTS-c declines with age [4]. No intervention study has tracked DNAm age, telomere length, or HbA1c after exogenous MOTS-c dosing [3][4].

Stress response and cellular resilience

In vitro and rodent work shows MOTS-c is induced under metabolic stress (fasting, exercise, oxidative challenge) and acts as a retrograde signal from mitochondria to nucleus, upregulating antioxidant and proteostasis genes [3][5]. Reynolds et al.'s 2021 NOD mouse work additionally suggested MOTS-c reduces autoimmune-mediated pancreatic β-cell destruction [6]. Human translation remains untested [1][4].

MOTS-c as an Exercise Mimetic: The 2021 Nature Findings

MOTS-c is described as an exercise mimetic because endogenous plasma MOTS-c rises acutely during exercise in humans, and exogenous administration reproduces several adaptations of training in mice. Every performance endpoint to date comes from rodent intervention, not human dosing trials [1][3]. The headline paper, Reynolds et al., "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline," was published in 2021 and had accumulated over 224 citations by early 2026 [1].

Study design and key outcomes

Reynolds and colleagues stratified C57BL/6 mice into young, middle-aged, and old cohorts and administered MOTS-c by intraperitoneal injection, then assessed running capacity, grip strength, and gait. Treated old mice ran further and showed improved physical function versus saline controls, with the largest relative gains in the aged group [1][3]. The Lee et al. 2015 protocol used 5 mg/kg IP daily; the exact Reynolds dose is not publicly verified in the open-access summaries available, so treat the dosing as approximate rather than authoritative [1][3].

The endogenous human signal

In the same body of work, plasma MOTS-c was measured in human participants and increased following acute exercise, indicating MOTS-c is a physiological mitochondrial signal during exertion rather than only a pharmacological agent [1]. This is the closest the literature comes to a human MOTS-c–exercise link, and it remains observational. No interventional trial as of early 2026 has administered synthetic MOTS-c to humans and measured VO₂max, time-to-exhaustion, or muscle biopsy AMPK activation [1][5].

MOTS-c Dosage: What Published Research Uses

There is no established human clinical dosage for MOTS-c as of early 2026, because no peer-reviewed interventional trial of synthetic MOTS-c administration in humans has been completed and no regulator, including the MHRA, has authorised it as a medicine [1][5]. Published dosing data come almost entirely from rodent work.

Rodent dosing in the primary literature

Lee et al. (Cell Metabolism, 2015) administered MOTS-c to mice by intraperitoneal injection at 5 mg/kg body weight, typically daily, in high-fat-diet and exercise paradigms. Secondary reviews in 2022–2023 consistently summarise the protocol at that dose [1][3]. Reynolds et al. (2021), working in a type 1 diabetes mouse model, also used IP injection, but the precise mg/kg is not disclosed in the open-access USC summary and the primary paper is paywalled, so treat the Reynolds dose as not publicly verified [5]. Broader rodent literature spans roughly 0.5–5 mg/kg IP or subcutaneous, daily or every-other-day, depending on the disease model [1][3].

Why rodent mg/kg does not translate to humans

Direct mg/kg conversion from mouse to human is unreliable for several reasons. Allometric scaling based on body surface area, rather than mass, would reduce a 5 mg/kg mouse dose to roughly 0.4 mg/kg human-equivalent on conventional FDA-style scaling. This assumes equivalent pharmacokinetics, which has not been demonstrated for MOTS-c. Route matters too: IP delivery in rodents bypasses first-pass effects in a way subcutaneous injection in humans does not.

MOTS-c is not approved for human use in the UK, has no MHRA marketing authorisation, and is prohibited at all times in sport as an AMPK activator under the WADA metabolic modulators class [4][5].

MOTS-c Side Effects and Safety Profile

MOTS-c has shown no major organ toxicity in published rodent studies at research doses up to 5 mg/kg IP, but no completed large-scale human safety trial exists as of early 2026, so its human side-effect profile remains formally uncharacterised [1][6]. The 2023 Cognitive Vitality profile states plainly that "MOTS-c therapeutic safety has not been established" in humans, citing only animal tolerance data and a short-term trial of the analogue CB4211, in which injection-site reactions were the most common finding.

Anecdotal reports from self-reported users describe increased heart rate, palpitations, injection-site irritation, insomnia, and fever. These are uncontrolled accounts, not pharmacovigilance data. No MOTS-c entries appear in MHRA Yellow Card, EMA, or FDA FAERS summaries because the peptide is not an approved medicine [6].

Theoretical risks worth flagging

• Hypoglycaemia. AMPK activation and improved insulin sensitivity in rodent models [1][4] imply a plausible risk of low blood glucose in humans, particularly in those already taking metformin, sulfonylureas, or insulin.
• Injection-site reactions. Subcutaneous peptide administration carries a known irritation risk, consistent with the CB4211 analogue data.
• Unknown long-term effects. Chronic systemic AMPK activation has not been characterised in humans for MOTS-c, and rodent studies rarely exceed a few weeks to months [1][4].

MOTS-c in the UK: Legal Status and MHRA Position (early 2026)

MOTS-c is not licensed as a medicine in the UK and is not a controlled drug under the Misuse of Drugs Act 1971. This places it in the same grey zone as most other research peptides: legal to manufacture, sell, and possess for in vitro laboratory use, but unlawful to market or supply for human consumption without a Marketing Authorisation from the MHRA.

As of early 2026, the MHRA has issued no MOTS-c-specific guidance, safety alert, or enforcement notice, and the peptide does not appear in the Drug Safety Update archive or in any UK public assessment report [3]. The position is therefore inferred from the general framework. Under the Human Medicines Regulations 2012, any substance presented as having properties for treating or preventing disease, or administered with a view to restoring physiological function, is a medicinal product by presentation or by function [3]. A peptide acting systemically on AMPK and glucose metabolism would meet the "by function" limb, and the MHRA's borderline products guidance treats such cases as medicinal by default [1].

What this means for UK researchers

MOTS-c is listed as a research-grade peptide for in vitro use — that label keeps the sale within the lawful research-chemical channel and does not confer any approval for self-administration. JCSG.org stocks Body Pharm MOTS-c for qualified UK researchers; see the current price and specification on the MOTS-c product page (supplied by bodypharm.co.uk — the manufacturer).

Three practical distinctions

• Purchase for in vitro work is lawful where the buyer is a bona fide researcher and the product is not held out for human use.
• Personal import or possession is not criminalised by the Misuse of Drugs Act 1971, but customs may still seize unlicensed medicinal products at the border.
• Supply or administration to humans without a Marketing Authorisation, Clinical Trial Authorisation, or Specials exemption breaches the Human Medicines Regulations 2012 [3][11].

MOTS-c and Anti-Doping: WADA and USADA Status in 2026

MOTS-c is prohibited at all times under the WADA Code as an AMP-activated protein kinase (AMPK) activator within the metabolic modulators class, not as a named S2 peptide hormone [1]. USADA's 2024 athlete guidance places it specifically under Section 4.4.1 (Activators of AMPK) and confirms that competitive athletes who use it face the same sanctions as those using any other listed metabolic modulator [1].

How the Prohibited List captures novel peptides

The WADA Prohibited List is republished each year and takes effect on 1 January. Peptide hormones, growth factors, and related substances sit under S2, but novel analogues are routinely captured by the "and other substances with similar chemical structure or biological effect" wording attached to each class [1]. MOTS-c's inclusion under metabolic modulators rather than S2 reflects its mechanism (AMPK activation, folate-purine flux) rather than structural similarity to growth hormones [1][3].

What UK athletes should do

Any UK athlete in a tested sport, or in a sport governed by a body that adopts the WADA Code, should treat MOTS-c as banned and contact UK Anti-Doping (UKAD) before any exposure, including handling research vials.

Human vs. Animal Evidence: An Honest Summary

The bulk of MOTS-c efficacy data is rodent or in vitro; no completed peer-reviewed interventional trial of synthetic MOTS-c in humans had been published by early 2026 [1][4]. That asymmetry should anchor how every benefit claim on this page is read.

In vitro and rodent foundations

The original mechanistic work (Lee et al., 2015) used cultured cells and mice given intraperitoneal MOTS-c at 5 mg/kg, typically daily, demonstrating AMPK activation, improved insulin sensitivity, and protection against high-fat-diet-induced obesity [1][6]. Reynolds et al. (2021) extended this to a murine type 1 diabetes model, reporting pancreatic β-cell protection following injected MOTS-c, though the exact mg/kg is not publicly verified outside the paywalled primary text [14]. The 2022 Cell Communication and Signaling review and the 2023 Frontiers in Endocrinology review both consolidate dozens of rodent studies on exercise capacity, inflammation, and metabolic stress, while explicitly stating that clinical translation is lacking [1][6].

What exists in humans

Human MOTS-c data is observational, not interventional. Cohort studies have measured endogenous circulating MOTS-c and correlated it with age, insulin resistance, obesity, and exercise capacity, with levels rising acutely during exercise and declining with age [1][6]. None of these involve administering exogenous MOTS-c. USADA's 2024 review reaches the same conclusion: no completed human trials [4].

How MOTS-c Compares to Related Research Peptides

MOTS-c vs. Humanin

Humanin and MOTS-c are both encoded within the mitochondrial 16S and 12S rRNA regions respectively, and both appear together in MDP reviews as cytoprotective signals [1]. They are not functionally interchangeable. Humanin is largely characterised as an anti-apoptotic peptide signalling through the FPR2 and CNTFR/WSX-1/gp130 receptor complex, whereas MOTS-c acts via the folate–methionine–purine axis to activate AMPK [1].

MOTS-c vs. NAD+ precursors

NAD+ is a redox cofactor, not a peptide, so the comparison is categorical rather than like-for-like. Both intersect mitochondrial energetics, but NAD+ feeds sirtuin and electron-transport chemistry whilst MOTS-c is a 16-amino-acid signalling molecule acting upstream of AMPK [1]. See the NAD+ research page for the cofactor pathway in detail.

MOTS-c vs. BPC-157 and GHK-Cu

BPC-157 is studied predominantly for gastrointestinal and tendon repair signalling in rodents, and GHK-Cu is a copper-binding tripeptide investigated for wound-healing and gene-expression effects. Neither shares MOTS-c's mitochondrial-encoded origin or its AMPK-centred metabolic mechanism. Researchers mapping the wider field can browse all peptides on JCSG.org and add to cart directly.

Key Research Papers on MOTS-c: A Curated Reading List

• Lee et al., Cell Metabolism, 2015 — the foundational paper identifying MOTS-c as a 16-amino-acid MDP that regulates insulin sensitivity and metabolic homeostasis via the folate-purine-AMPK axis, using 5 mg/kg intraperitoneal dosing in high-fat-diet mice [9][11].
• Reynolds et al., 2021 — extended MOTS-c into exercise physiology and type 1 diabetes models in mice, reporting preserved pancreatic β-cell function after MOTS-c injection [12].
• Kim et al., Cell Communication and Signaling, 2022 (PMC9905433) — a mechanistic review consolidating MOTS-c's roles in metabolic stress, inflammation and exercise tolerance, whilst flagging the absence of clinical data [11].
• Zheng et al., Frontiers in Endocrinology, 2023 (PMC9854231) — the most current comprehensive review covering endogenous MOTS-c decline with age, observational human correlations and the rodent intervention evidence [9].
• ADDF Cognitive Vitality MOTS-c profile, 2023 — a structured evidence appraisal noting that "therapeutic safety has not been established" in humans [10].

Frequently Asked Questions About MOTS-c

Is MOTS-c the same as a hormone?

MOTS-c is not classified as a classical hormone but as a mitochondrial-derived peptide (MDP) encoded within the MT-RNR1 region of mitochondrial DNA [1]. It acts as a signalling molecule with hormone-like systemic effects, notably AMPK activation and modulation of glucose metabolism, but lacks the endocrine gland origin and receptor specificity that define hormones [1].

Does MOTS-c occur naturally in the human body?

Yes. MOTS-c is endogenously produced from the mitochondrial 12S rRNA region and circulates in human plasma, with levels that decline with age and correlate inversely with insulin resistance and obesity in observational cohorts [1].

Can I buy MOTS-c for research in the UK?

MOTS-c has no MHRA marketing authorisation as of early 2026. JCSG.org stocks Body Pharm research-grade MOTS-c vials for qualified UK researchers — order on the product page and check the live price in the buy box. Supplied for in vitro research use only; not for human consumption.

Is MOTS-c banned in sport?

Yes. USADA's 2024 guidance confirms MOTS-c is prohibited at all times under Section 4.4 of the WADA Prohibited List as an AMPK activator within metabolic modulators, rather than as a named S2 peptide [3].

How does MOTS-c differ from other mitochondrial-derived peptides?

MOTS-c is a 16-amino-acid peptide encoded by MT-RNR1 that signals primarily via the folate-purine-AMPK axis [1]. Humanin, encoded by MT-RNR2, is structurally distinct and acts mainly as a cytoprotective and anti-apoptotic peptide; no head-to-head comparative trials between the two have been published as of early 2026 [1].

How is MOTS-c administered in research settings?

In Lee et al. 2015, MOTS-c was administered to mice by intraperitoneal injection at 5 mg/kg body weight, typically daily, in high-fat-diet models [1]. No validated human dosing protocol exists. For wider context, see our full peptides research library on JCSG.org.

Order MOTS-c on JCSG.org — UK Delivery

JCSG.org is the UK's dedicated research-peptide destination for Body Pharm products. Go to the MOTS-c product page to see the current price, vial specification, and add to cart. For the complete catalogue of mitochondrial-derived and metabolic peptides, browse all peptides available for UK delivery.

Order MOTS-c Now →

Sold for in vitro research use only. Not for human consumption. No MHRA marketing authorisation.